Performance enhancement drugs: what they are, what they do, and what they cost

Performance enhancement drugs sit at an awkward intersection of medicine, sport, vanity, and desperation. In clinics, I see the legitimate side every week: people with real disease who need hormones, stimulants, pain control, or respiratory medications to function normally. Then I see the shadow version—healthy people chasing an edge, a look, or a feeling. The same molecules can live in both worlds. That’s what makes this topic so clinically relevant and so easy to misunderstand.

“Performance” is a slippery word. For an endurance athlete, it might mean oxygen delivery and fatigue resistance. For a student, it might mean focus and wakefulness. For a middle-aged patient, it might mean libido, erections, or energy. For a bodybuilder, it often means muscle size, leanness, and recovery. The drug categories overlap, and the marketing language online blurs the boundaries even further. Patients tell me they read a forum thread and felt they’d found a “safe shortcut.” The human body is messy. Shortcuts rarely stay short.

This article takes a medical, evidence-based look at performance enhancement drugs: what counts as a “PED,” which ones have real therapeutic roles, what the science supports, and where the myths thrive. We’ll cover major classes (anabolic-androgenic steroids, erythropoiesis-stimulating agents, stimulants, beta-2 agonists, growth hormone and related peptides, and more), along with risks, contraindications, and interactions. We’ll also talk about the social and market context—counterfeits, online “clinics,” and why people keep taking these risks even when they know better.

If you want a quick orientation before diving in, start with our overview of medication safety basics. It’s not glamorous, but it prevents a lot of harm.

Medical applications

One reason this topic gets so tangled is that many “performance” drugs are simply medications used outside their intended medical context. In a hospital chart, they’re tools. In a locker room, they’re leverage. The molecule doesn’t change; the risk-benefit calculation does.

2.1 Primary indication: treating disease, not “enhancing” health

There is no single generic drug called “performance enhancement drugs.” Instead, the term describes a group of medications and substances used to improve strength, speed, endurance, alertness, appearance, or sexual performance. In medicine, these same agents are prescribed for specific diagnoses with clear goals: restoring normal physiology, preventing complications, or improving function and quality of life.

Here are the major therapeutic classes most often pulled into the “performance enhancement” conversation, with their legitimate medical roles:

Anabolic-androgenic steroids (AAS) (therapeutic class: androgen/anabolic steroid). Generic names include testosterone (various esters), nandrolone, oxandrolone, stanozolol (varies by country), and others. Brand names vary widely by formulation and region. In clinical practice, testosterone is used for male hypogonadism (documented low testosterone with symptoms) and certain gender-affirming regimens under specialist care. Some anabolic agents have been used for specific wasting states, though modern practice is cautious and indication-dependent.
Erythropoiesis-stimulating agents (ESAs) (therapeutic class: hematopoietic growth factor). Generic names include epoetin alfa and darbepoetin alfa. Brand names include Epogen/Procrit (epoetin alfa) and Aranesp (darbepoetin alfa). Primary medical use: anemia related to chronic kidney disease and selected chemotherapy-associated anemia under strict protocols.
Central nervous system stimulants (therapeutic class: sympathomimetic stimulant). Generic names include amphetamine/dextroamphetamine, methylphenidate, lisdexamfetamine, and modafinil/armodafinil (wakefulness-promoting agents). Brand names include Adderall, Ritalin, Vyvanse, Provigil, and Nuvigil. Primary medical uses: ADHD (for several agents) and narcolepsy/shift-work sleep disorder (for certain agents).
Beta-2 agonists (therapeutic class: bronchodilator). Generic names include albuterol (salbutamol), formoterol, salmeterol, and others. Brand names include Ventolin/ProAir (albuterol), Serevent (salmeterol), and Foradil (formoterol; availability varies). Primary medical use: asthma and COPD symptom control.
Phosphodiesterase-5 (PDE5) inhibitors (therapeutic class: PDE5 inhibitor). Generic names include sildenafil and tadalafil. Brand names include Viagra (sildenafil), Cialis (tadalafil), and Revatio (sildenafil for pulmonary arterial hypertension). Primary medical uses: erectile dysfunction and pulmonary arterial hypertension (specific dosing and formulation decisions are clinician-led).
Human growth hormone (somatropin) (therapeutic class: pituitary growth hormone). Generic name: somatropin. Brand names include Genotropin, Humatrope, Norditropin, Saizen, and others. Primary medical uses: growth hormone deficiency (pediatric and adult), certain growth disorders, and specific wasting indications depending on jurisdiction.
Diuretics (therapeutic class: diuretic; several subclasses). Generic names include furosemide, hydrochlorothiazide, spironolactone, and others. Brand names include Lasix (furosemide) and Aldactone (spironolactone). Primary medical uses: hypertension, heart failure, edema from liver/kidney disease, and other conditions.

When these drugs are used medically, the goal is not “superhuman.” It’s stability. It’s preventing hospitalization. It’s getting someone through a workday without wheezing, fainting, or falling asleep at the wheel. That context matters.

2.2 Approved secondary uses (selected examples)

Several of these medications have more than one approved indication, which is part of why they show up in non-medical “optimization” culture.

Sildenafil (PDE5 inhibitor): beyond erectile dysfunction, sildenafil is also used under the brand Revatio for pulmonary arterial hypertension, where it improves pulmonary vascular dynamics and exercise capacity in a disease state. Patients with PAH are not “enhancing”; they’re trying to breathe and walk without severe limitation.
Tadalafil (PDE5 inhibitor): in addition to erectile dysfunction, tadalafil is approved for benign prostatic hyperplasia (BPH) symptoms in many regions, improving urinary symptoms in selected patients.
Stimulants: while ADHD is the best-known indication, certain agents are approved for narcolepsy and related sleep-wake disorders. That’s a very different clinical scenario than using stimulants to cram for exams or to train longer.
Beta-2 agonists: these are cornerstone therapies for asthma/COPD symptom relief. Their presence in sport is complicated because airway disease is common, and treatment is legitimate when properly diagnosed and documented.

In my experience, confusion starts when people assume that a drug that improves function in disease will automatically improve function in health. Sometimes it doesn’t. Sometimes it does, but at a price that only becomes obvious months later.

2.3 Off-label uses (clearly off-label)

Off-label prescribing is legal and common in medicine, but it is not casual. It requires a clinician to weigh evidence quality, alternatives, and patient-specific risk. In the performance world, “off-label” often becomes “no-label,” meaning no clinician, no monitoring, and no plan for complications.

Examples of off-label patterns that clinicians sometimes encounter (not endorsements):

Testosterone or other androgens for nonspecific fatigue, low mood, or “low T” symptoms without clear biochemical hypogonadism. This is controversial and can be inappropriate when driven by marketing rather than diagnosis.
Modafinil used off-label for fatigue in certain neurologic or medical conditions. Evidence varies by condition, and side effects and interactions still matter.
Beta-2 agonists used inappropriately for “fat loss” or training intensity. This is not a medical indication and can provoke cardiovascular symptoms.

Patients sometimes ask me, “If it’s prescribed off-label, doesn’t that mean it’s basically safe?” No. It means a clinician is taking responsibility for a nuanced decision, ideally with follow-up and monitoring. That’s the difference.

2.4 Experimental / emerging uses (where evidence is limited)

Performance enhancement culture loves “cutting-edge” biology: peptides, hormone secretagogues, selective androgen receptor modulators (SARMs), and research chemicals sold with a wink. The problem is that “emerging” often translates to “insufficient evidence” and “unknown long-term risk.”

SARMs: these are not approved for bodybuilding or athletic enhancement, and products marketed as SARMs have a history of quality and labeling concerns. Research interest exists for muscle wasting and osteoporosis, but clinical translation has been slow and safety questions persist.
Peptides and growth hormone secretagogues: marketed online for recovery, sleep, or body composition. Evidence for many of these compounds in healthy people is weak, and contamination or mislabeling is a recurring concern.
Novel stimulants: “pre-workout” and “nootropic” markets periodically cycle through new compounds. The pharmacology can be unpredictable, and adverse event patterns often show up after widespread use.

If you want a deeper dive into how clinical evidence is graded (and why early studies can mislead), see our guide to interpreting medical research.

Risks and side effects

Side effects are not moral punishment. They’re physiology. When you push one pathway, another pathway pushes back. On a daily basis I notice that people underestimate the “boring” harms—blood pressure, sleep disruption, anxiety, reflux—because they don’t sound dramatic. Then those boring harms accumulate.

3.1 Common side effects

Common effects vary by class, dose, route, and individual vulnerability. Still, certain patterns show up repeatedly in clinical practice and in adverse event reports:

Anabolic-androgenic steroids: acne, oily skin, hair loss in genetically susceptible individuals, mood changes (irritability, agitation), sleep disturbance, fluid retention, and changes in libido. In people with ovaries, virilizing effects (voice deepening, increased body hair, menstrual disruption) can occur and may be irreversible.
Stimulants: reduced appetite, insomnia, jitteriness, palpitations, dry mouth, headaches, and anxiety. People often describe feeling “productive” while their sleep debt quietly grows.
PDE5 inhibitors: headache, flushing, nasal congestion, indigestion, and dizziness. Visual changes can occur with some agents.
Beta-2 agonists: tremor, palpitations, nervousness, and low potassium in susceptible situations, especially with high use.
ESAs: injection-site reactions and flu-like symptoms can occur, but the bigger concerns are in the serious category below.
Diuretics: frequent urination, dehydration, cramps, dizziness, and electrolyte disturbances.

One practical reality: people who self-prescribe often stack multiple agents. That makes it harder to identify what’s causing what, and it increases the chance that a “minor” symptom is actually an early warning sign.

3.2 Serious adverse effects

Serious harms are less common than nuisance side effects, but they are the reason clinicians treat these drugs with respect. When I’m asked, “What’s the worst that can happen?” I try not to be theatrical. I also don’t sugarcoat it.

Cardiovascular events: stimulants and anabolic steroids can raise blood pressure and strain the heart. ESAs can increase blood viscosity by raising red blood cell mass, which is linked to higher risk of thrombosis when misused. Heart attack, stroke, arrhythmias, and sudden cardiac death are documented risks in certain contexts.
Blood clots (thromboembolism): risk rises with increased hematocrit (ESAs), dehydration (diuretics), and certain hormone exposures. Symptoms like sudden chest pain, shortness of breath, one-sided leg swelling, or neurologic deficits require urgent evaluation.
Liver injury: some oral anabolic steroids (particularly 17-alpha-alkylated compounds) are associated with hepatotoxicity. Jaundice, dark urine, severe abdominal pain, or unexplained fatigue should not be ignored.
Psychiatric effects: severe anxiety, panic, aggression, and mood instability can occur with stimulants and androgens. In vulnerable individuals, psychosis or severe depression can emerge.
Endocrine suppression and infertility: exogenous androgens suppress the hypothalamic-pituitary-gonadal axis. Testicular atrophy, low sperm count, and infertility can follow. Recovery is unpredictable.
Infections and injection complications: non-sterile injections raise risk of abscesses and blood-borne infections. Even with sterile technique, improper injection can cause tissue injury.

Urgent symptoms that warrant immediate medical attention include chest pain, fainting, severe shortness of breath, sudden weakness or numbness, severe headache with neurologic changes, confusion, and signs of severe allergic reaction.

3.3 Contraindications and interactions

Contraindications depend on the specific drug, but several high-risk themes recur across performance enhancement drugs:

PDE5 inhibitors + nitrates (nitroglycerin and related drugs): this combination can cause dangerous hypotension. This is one of the clearest “do not mix” rules in medicine.
Stimulants + other sympathomimetics (decongestants, certain “fat burners,” high-caffeine products): additive effects can provoke tachycardia, hypertension, anxiety, and arrhythmias.
Stimulants + certain antidepressants: interactions vary by agent, but risks can include blood pressure elevation and, with some combinations, serotonin toxicity.
Androgens + underlying prostate or breast cancer: testosterone therapy is not appropriate in several cancer contexts and requires careful evaluation and monitoring when used medically.
ESAs + uncontrolled hypertension: ESAs can worsen blood pressure control and increase thrombotic risk when misused.
Diuretics + lithium, digoxin, or other electrolyte-sensitive drugs: electrolyte shifts can increase toxicity risk.
Alcohol: it doesn’t “cancel out” stimulants; it often masks impairment and increases risky behavior. With PDE5 inhibitors, alcohol can worsen dizziness and hypotension. With androgens, heavy alcohol use adds liver and cardiovascular strain.

Safety hinges on the full medication list, supplements included. Patients are often surprised when I ask about “pre-workout,” sleep aids, and herbal products. Those count. They interact.

Beyond medicine: misuse, myths, and public misconceptions

Misuse is not limited to elite sport. I see it in recreational gyms, in college libraries at 2 a.m., and in people who simply feel left behind by aging. The internet has turned pharmacology into a hobby. That’s not entirely bad—health literacy is good—but the confidence-to-competence ratio online can be breathtaking.

4.1 Recreational or non-medical use

Non-medical use tends to cluster into a few predictable goals:

Muscle and physique: anabolic steroids, SARMs, growth hormone, insulin misuse, thyroid hormone misuse, and diuretics (especially around competitions or photo shoots).
Endurance: ESAs, stimulants, and sometimes beta-2 agonists, with the belief that “more oxygen” or “more drive” equals better performance.
Focus and productivity: prescription stimulants and wakefulness agents used without a diagnosis, often combined with caffeine and sleep restriction.
Sexual performance: PDE5 inhibitors used as “insurance,” sometimes mixed with alcohol or recreational drugs.

Expectations are often inflated because early effects can feel dramatic: a few nights of less sleep, a few weeks of faster recovery, a sudden pump in the gym. Then tolerance, side effects, or endocrine suppression shows up. Patients tell me, “I felt great until I didn’t.” That sentence comes up more than you’d think.

4.2 Unsafe combinations

Stacking is where risk accelerates. Combining stimulants with high-dose caffeine, yohimbine-like compounds, or decongestants is a common recipe for palpitations and panic. Mixing PDE5 inhibitors with nitrates is medically dangerous. Combining diuretics with dehydration and intense training can trigger electrolyte derangements that affect heart rhythm. Add alcohol or cocaine to the mix and the physiology becomes a coin toss.

One of the most deceptive combinations is “upper + downer”: stimulants to train or work, then sedatives or alcohol to sleep. The person feels in control. Their autonomic nervous system disagrees.

4.3 Myths and misinformation

Myth: “If a doctor prescribes it, it’s safe for anyone.” Reality: prescriptions are tied to diagnoses, dosing strategies, monitoring, and contraindications. Remove those guardrails and the risk profile changes.
Myth: “Natural” supplements are safer than drugs. Reality: “natural” is a marketing term, not a safety category. Supplements can be contaminated, mislabeled, or pharmacologically active in unpredictable ways.
Myth: “You can ‘cycle’ and avoid long-term harm.” Reality: endocrine systems do not read forum schedules. Some harms are dose-related, some are idiosyncratic, and some accumulate silently (blood pressure, lipids, cardiac remodeling).
Myth: “Everyone is doing it, so it must be fine.” Reality: prevalence is not proof of safety. It’s proof of social pressure and availability.

If you’re sorting myths from evidence, it helps to understand how adverse effects are detected and reported. Our primer on drug side-effect reporting walks through the basics.

Mechanism of action (in plain language)

Performance enhancement drugs work by shifting normal physiology in predictable directions. The details differ by class, but the theme is the same: they amplify a pathway that the body already uses to regulate energy, oxygen delivery, muscle protein balance, attention, or vascular tone.

Anabolic-androgenic steroids (AAS)

AAS bind to the androgen receptor in many tissues, including muscle. Activation of this receptor changes gene transcription, increasing protein synthesis and altering recovery signaling. That’s why muscle size and strength can increase. The same receptor activity affects skin, hair follicles, the brain, the liver, and reproductive organs. That’s why side effects are not “random.” They’re receptor biology.

Erythropoiesis-stimulating agents (ESAs)

ESAs mimic the action of endogenous erythropoietin, stimulating the bone marrow to produce more red blood cells. More red blood cells can increase oxygen-carrying capacity. In anemia due to kidney disease, that can reduce transfusion needs and improve symptoms. In a healthy person, pushing hematocrit upward can thicken blood and increase clot risk, especially with dehydration or underlying cardiovascular disease.

Stimulants and wakefulness agents

Classic stimulants increase synaptic signaling of catecholamines (dopamine and norepinephrine) in key brain circuits. That can improve attention and reduce impulsivity in ADHD, and it can promote wakefulness. It can also raise heart rate, blood pressure, and anxiety. Modafinil’s mechanism is more complex and not identical to amphetamines, but it still alters wakefulness networks and can disrupt sleep architecture.

PDE5 inhibitors

PDE5 inhibitors block the enzyme phosphodiesterase type 5, increasing cyclic GMP in smooth muscle cells. In the penis, that supports relaxation of vascular smooth muscle and improved blood flow during sexual stimulation. Without sexual stimulation, the pathway is not strongly activated, which is why these drugs don’t create arousal out of thin air. In pulmonary arterial hypertension, the same signaling pathway affects pulmonary vascular tone.

Mechanisms are elegant. Outcomes are not always. Biology rarely offers a free lunch.

Historical journey

Performance enhancement drugs did not begin as a single industry. They emerged from legitimate medical discoveries—hormones, hematology, respiratory medicine, psychiatry—then migrated into sport and popular culture. The timeline is a patchwork, and it’s full of unintended consequences.

6.1 Discovery and development

Testosterone was isolated and synthesized in the early 20th century, and anabolic steroid derivatives followed as chemists explored how structural tweaks changed anabolic versus androgenic effects. Clinicians used these agents for hypogonadism and certain catabolic states. Athletes noticed the muscle effects quickly. That part is not mysterious; it’s pharmacology doing what it does.

Erythropoietin biology became clinically actionable later, with recombinant human erythropoietin transforming anemia management in chronic kidney disease. It was a major medical advance. It also created a new temptation in endurance sports: increasing red cell mass without altitude training. The misuse story grew alongside the therapeutic story.

Stimulants have a long and complicated history, from early amphetamine use to modern ADHD treatment frameworks. In the clinic, they can be life-changing for properly diagnosed ADHD. Outside the clinic, they became tools for wakefulness, appetite suppression, and “grind culture.” Patients sometimes joke that they want “a prescription for motivation.” I understand the impulse. Motivation is not a neurotransmitter you can safely dial to 11.

PDE5 inhibitors are a classic example of targeted pathway pharmacology becoming a household name. Their visibility changed public conversations about erectile dysfunction and, indirectly, about cardiovascular risk and men’s health. That visibility also fueled casual, non-medical use.

6.2 Regulatory milestones

Regulatory approvals generally followed evidence for specific diseases: testosterone formulations for hypogonadism, ESAs for anemia in defined contexts, stimulants for ADHD and narcolepsy, PDE5 inhibitors for erectile dysfunction and pulmonary arterial hypertension, and growth hormone for deficiency states. Anti-doping regulations evolved in parallel as sports organizations tried to keep competition fair and reduce harm. The two systems—medical regulation and sport regulation—overlap but do not share identical goals.

6.3 Market evolution and generics

As patents expired, generics expanded access for legitimate patients. That’s a public health win. At the same time, broader availability created more diversion, more online gray-market sales, and more counterfeits. I often see people assume that “generic” means “sketchy.” In regulated pharmacies, generics are held to quality standards. The sketchiness usually comes from the supply chain, not the concept of a generic drug.

Society, access, and real-world use

This is the part that feels less like pharmacology and more like anthropology. Why do people take these risks? Because performance is currency. Because aging is humbling. Because social media rewards extremes. Because injuries happen and patience runs out. I’ve had patients look me in the eye and say, “I just want to feel like myself again,” and then describe a plan they found on a message board that would make any endocrinologist wince.

7.1 Public awareness and stigma

Some performance-related medications reduced stigma by naming treatable conditions. PDE5 inhibitors made erectile dysfunction discussable. ADHD medications brought attention to neurodevelopmental differences, though they also sparked backlash and misunderstanding. Testosterone therapy became a cultural lightning rod, partly because true hypogonadism is real and treatable, and partly because “low T” marketing blurred the line between disease and dissatisfaction.

Stigma cuts both ways. People with legitimate asthma sometimes feel accused of “cheating” when they use inhalers. People with legitimate ADHD sometimes feel pressured to justify treatment. Meanwhile, people misusing drugs often hide it until complications force the issue. Silence is not a safety strategy.

7.2 Counterfeit products and online pharmacy risks

Counterfeits are not a theoretical problem. They are a daily reality in many markets. Products sold as anabolic steroids, growth hormone, or “research peptides” can contain the wrong drug, the wrong dose, contaminants, or nothing at all. Even when the label matches the contents, sterility and storage conditions are unknown. That’s how abscesses happen. That’s how unexpected toxicity happens.

Online “pharmacies” and telehealth-like storefronts also vary wildly in quality. Some are legitimate and regulated; others are essentially marketing funnels. A common red flag is a site that offers prescription-only drugs with minimal screening, no meaningful medical history review, and no plan for follow-up. Another red flag is language that promises transformation rather than treatment. Medicine rarely promises transformation. It offers probabilities.

7.3 Generic availability and affordability

Generic versions of several drugs discussed here—such as sildenafil, tadalafil, many stimulants, and many diuretics—have improved affordability for patients who truly need them. In clinical practice, the choice between brand and generic is usually about formulation, tolerability, insurance coverage, and availability, not about “strength.” When people buy outside regulated channels, cost savings can be illusory if the product is counterfeit or unsafe.

7.4 Regional access models (OTC / prescription / pharmacist-led)

Access rules differ by country and sometimes by state or province. Some regions allow pharmacist-led access for certain medications; others require a clinician’s prescription and ongoing monitoring. Anti-doping rules in sport add another layer that is separate from medical legality. If you compete, you already know the paperwork can be maddening. Still, the paperwork exists for a reason: it documents diagnosis, protects athletes with real disease, and reduces the incentive for covert misuse.

For readers navigating neurodevelopmental topics and medication myths, our ADHD medication explainer addresses common misconceptions without the usual internet shouting match.

Conclusion

Performance enhancement drugs are not one drug and not one story. They include hormones, stimulants, blood-building agents, bronchodilators, vasodilators, and diuretics—many of which are valuable, even lifesaving, when used for their approved indications under medical supervision. The same agents can cause serious harm when used to chase an edge, especially when stacked, sourced from unreliable sellers, or taken without monitoring.

If there’s a single practical takeaway, it’s this: the body adapts, and it keeps receipts. Short-term gains can be followed by long-term costs—cardiovascular strain, endocrine suppression, psychiatric effects, liver injury, and clot risk among them. Myths thrive because early effects feel convincing, and because online anecdotes are louder than clinic follow-up.

This article is for general information and does not replace individualized medical care. If you’re considering, already using, or worried about performance enhancement drugs, a confidential conversation with a qualified clinician is the safest next step—especially before mixing substances or stopping prescribed therapy abruptly.